- Home
- GOSS vs NHIC Comparison
GOSS vs NHIC Comparison
Compare GOSS & NHIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- NHIC
- Stock Information
- Founded
- GOSS 2015
- NHIC 2024
- Country
- GOSS United States
- NHIC United States
- Employees
- GOSS N/A
- NHIC N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- NHIC
- Sector
- GOSS Health Care
- NHIC
- Exchange
- GOSS Nasdaq
- NHIC NYSE
- Market Cap
- GOSS 262.5M
- NHIC 276.7M
- IPO Year
- GOSS 2019
- NHIC 2025
- Fundamental
- Price
- GOSS $1.40
- NHIC $10.21
- Analyst Decision
- GOSS Strong Buy
- NHIC
- Analyst Count
- GOSS 4
- NHIC 0
- Target Price
- GOSS $7.75
- NHIC N/A
- AVG Volume (30 Days)
- GOSS 1.3M
- NHIC 2.9K
- Earning Date
- GOSS 08-11-2025
- NHIC 01-01-0001
- Dividend Yield
- GOSS N/A
- NHIC N/A
- EPS Growth
- GOSS N/A
- NHIC N/A
- EPS
- GOSS N/A
- NHIC N/A
- Revenue
- GOSS $124,590,000.00
- NHIC N/A
- Revenue This Year
- GOSS N/A
- NHIC N/A
- Revenue Next Year
- GOSS $91.14
- NHIC N/A
- P/E Ratio
- GOSS N/A
- NHIC N/A
- Revenue Growth
- GOSS N/A
- NHIC N/A
- 52 Week Low
- GOSS $0.55
- NHIC $10.02
- 52 Week High
- GOSS $1.55
- NHIC $10.55
- Technical
- Relative Strength Index (RSI)
- GOSS 57.95
- NHIC N/A
- Support Level
- GOSS $1.22
- NHIC N/A
- Resistance Level
- GOSS $1.36
- NHIC N/A
- Average True Range (ATR)
- GOSS 0.08
- NHIC 0.00
- MACD
- GOSS -0.00
- NHIC 0.00
- Stochastic Oscillator
- GOSS 66.07
- NHIC 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NHIC NEWHOLD INVESTMENT CORP III
NewHold Investment Corp III is a blank check company.